Corvus Pharmaceuticals (CRVS) Financials

Corvus Pharmaceuticals’ latest quarter shows a company with a very strong cash position, but one that is still operating at a meaningful loss and burning cash on a quarterly basis. For biotech investors, that usually means the story remains centered on clinical progress and the balance sheet runway rather than near-term profitability.

• Cash and investments are substantial: At the end of Q1 2026, Corvus held about $236.7 million in cash, short-term investments, and long-term investments, which gives it a large operating cushion.
• Liquidity improved sharply year over year: Total current assets rose to $239.9 million from $45.5 million in Q1 2025, largely reflecting financing activity and a larger investment portfolio.
• Balance sheet remains lightly levered: Total liabilities were only $12.5 million versus $240.7 million of common equity, so the company is not burdened by meaningful debt.
• Asset growth outpaced liabilities: Total assets climbed to $253.2 million from $59.4 million a year earlier, indicating a much stronger financial base.
• Financing bolstered runway: Q1 2026 included $189.4 million of common equity issuance, which significantly strengthened the cash position.
• Operating losses remain sizable: Q1 2026 net loss was $13.7 million, compared with $12.3 million in Q4 2025 and $8.0 million in Q2 2025, showing expenses are still running above revenue generation.
• No product revenue yet: Revenue was $0 in the latest quarter, so the business is still pre-commercial and depends on funding and clinical execution.
• R&D remains the main cost driver: Research and development expense was $11.2 million in Q1 2026, up from $10.0 million in Q4 2025 and $7.9 million in Q2 2025, underscoring ongoing pipeline investment.
• Operating cash burn is still significant: Cash used in operations was $10.4 million in Q1 2026, and the company also spent heavily on investments, resulting in a large quarter-over-quarter cash deployment profile.
• Share count has risen: Weighted average basic shares were 90.0 million in Q1 2026 versus 72.1 million in Q1 2025, which suggests dilution from capital raising.

Looking at the last four years, Corvus has moved from a smaller cash base in 2023 and early 2024 to a much stronger liquidity position in 2026. That is a positive for survival and development flexibility. However, the core operating picture has not changed much: no revenue, recurring losses, and ongoing cash burn. For investors, the key question is whether the company can convert its large cash reserve into meaningful clinical milestones before dilution becomes a bigger concern.